<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982227</url>
  </required_header>
  <id_info>
    <org_study_id>1208138</org_study_id>
    <secondary_id>2012-004314-34</secondary_id>
    <nct_id>NCT01982227</nct_id>
  </id_info>
  <brief_title>Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.</brief_title>
  <official_title>Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 30% and 40% of patients with colorectal cancer develop metastatic disease&#xD;
      intraperitoneally. The optimal treatment of this disease combines surgery and chemotherapy&#xD;
      but requires resection of all lesions larger than 2mm.&#xD;
&#xD;
      Indocyanine green has an affinity for tumor tissues and the interest of its use has been&#xD;
      demonstrated for the detection of sentinel lymph node and some liver surgeries.&#xD;
&#xD;
      The ability of indocyanine green to detect peritoneal carcinomatosis in humans has never been&#xD;
      evaluated.&#xD;
&#xD;
      This study aims to evaluate the diagnostic performance of fluorescence in the detection of&#xD;
      malignant cells in peritoneal carcinomatosis of colorectal origin compared with pathological&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo peritoneal cancer index (PCI) score with and without fluorescence</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence</measure>
    <time_frame>At de begining of the surgery</time_frame>
    <description>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green</intervention_name>
    <description>intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.</description>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with progressive colorectal cancer in intra-abdominal surgery requiring resection&#xD;
        +/- Chemotherapy Hyperthermic Intraperitoneal&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with progressive colorectal cancer in intra-abdominal surgery requiring&#xD;
             resection + / - Chemotherapy Hyperthermic Intraperitoneal&#xD;
&#xD;
          -  Aged 18 to 70 inclusive&#xD;
&#xD;
          -  Signature information form and consent by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, a urine pregnancy test or blood will be realized within 72 hours&#xD;
             before surgery&#xD;
&#xD;
          -  Contraindication to surgery&#xD;
&#xD;
          -  Diagnosis not confirmed colorectal adenocarcinoma&#xD;
&#xD;
          -  Persons major subject of legal protection or unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabrielle BARABINO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer metastatic</keyword>
  <keyword>indocyanine green</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

